Prognostic Value of Fibrosis-4 in Male Patients with Alcohol-Related Hepatocellular Carcinoma: Implications for Ultrasound-Based Therapeutic Strategies

<b><i>Background:</i></b> Hepatocellular carcinoma (HCC) is still the largest cause of cancer-related death globally, with alcohol-related HCC (AR-HCC) being a particularly difficult subtype with poor clinical results. Noninvasive biomarkers, such as the fibrosis-4 (FIB-4) index, may provide significant prognostic information that might aid in guiding new interventional techniques, such as ultrasound-based treatments. <b><i>Methods:</i></b> The authors did a retrospective cohort analysis on male AR-HCC patients diagnosed between January 2008 and December 2018. Clinical data and survival outcomes were obtained from electronic medical records, with HCC diagnosed as the baseline. The major endpoint was 12-month mortality. Multivariate logistic regression and limited cubic spline analysis were used to assess the relationship between FIB-4 and mortality risk. <b><i>Results:</i></b> Among 786 AR-HCC patients (mean age 57 years), 90.1% reported a history of alcohol usage for more than 10 years. The Barcelona Clinic Liver Cancer staging showed 42.8% in stage 0/A, 45.9% in stage B/C, and 11.3% in stage D. Deceased individuals had substantially higher FIB-4 levels (<i>p</i> < 0.05). Logistic regression demonstrated that higher FIB-4 was independently related with increased mortality, and spline analysis revealed a linear risk increase with a threshold of 5.61. <b><i>Conclusion:</i></b> Elevated FIB-4 (≥5.61) predicts worse mortality in AR-HCC, indicating its potential relevance in stratifying patients for ultrasound-based cancer therapy. The level of fibrosis may impact both therapeutic response and procedural risk. Routine incorporation of FIB-4 into clinical processes may aid precision decision-making in choosing AR-HCC patients most likely to benefit from ultrasound-guided or ultrasound-enhanced biotherapeutic. <b>Keywords:</b> alcohol, hepatocellular carcinoma, FIB-4, multivariate logistic regression analyses, mortality.

Authors

Institutions

Publication Details

Journal
Cancer Biotherapy and Radiopharmaceuticals
Published
2025-11-21
DOI
https://doi.org/10.1177/10849785251398953
Primary Topic
Hepatocellular Carcinoma Treatment and Prognosis
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Prognostic Value of Fibrosis-4 in Male Patients with Alcohol-Related Hepatocellular Carcinoma: Implications for Ultrasound-Based Therapeutic Strategies

Wen‐Chang Wang, Binxia Chang, Mengwen He, Dong Ji et al.
Cancer Biotherapy and Radiopharmaceuticals
Hepatocellular Carcinoma Treatment and Prognosis
article

Prognostic Value of Fibrosis-4 in Male Patients with Alcohol-Related Hepatocellular Carcinoma: Implications for Ultrasound-Based Therapeutic Strategies

Wen‐Chang Wang, Binxia Chang, Mengwen He, Dong Ji, Xu-Yang Li, Jianjun Wang, Chunyan Wang, Chang Guo, Wucai Yang, Yiming Fu, Yifan Guo
article en

Abstract

<b><i>Background:</i></b> Hepatocellular carcinoma (HCC) is still the largest cause of cancer-related death globally, with alcohol-related HCC (AR-HCC) being a particularly difficult subtype with poor clinical results. Noninvasive biomarkers, such as the fibrosis-4 (FIB-4) index, may provide significant prognostic information that might aid in guiding new interventional techniques, such as ultrasound-based treatments. <b><i>Methods:</i></b> The authors did a retrospective cohort analysis on male AR-HCC patients diagnosed between January 2008 and December 2018. Clinical data and survival outcomes were obtained from electronic medical records, with HCC diagnosed as the baseline. The major endpoint was 12-month mortality. Multivariate logistic regression and limited cubic spline analysis were used to assess the relationship between FIB-4 and mortality risk. <b><i>Results:</i></b> Among 786 AR-HCC patients (mean age 57 years), 90.1% reported a history of alcohol usage for more than 10 years. The Barcelona Clinic Liver Cancer staging showed 42.8% in stage 0/A, 45.9% in stage B/C, and 11.3% in stage D. Deceased individuals had substantially higher FIB-4 levels (<i>p</i> < 0.05). Logistic regression demonstrated that higher FIB-4 was independently related with increased mortality, and spline analysis revealed a linear risk increase with a threshold of 5.61. <b><i>Conclusion:</i></b> Elevated FIB-4 (≥5.61) predicts worse mortality in AR-HCC, indicating its potential relevance in stratifying patients for ultrasound-based cancer therapy. The level of fibrosis may impact both therapeutic response and procedural risk. Routine incorporation of FIB-4 into clinical processes may aid precision decision-making in choosing AR-HCC patients most likely to benefit from ultrasound-guided or ultrasound-enhanced biotherapeutic. <b>Keywords:</b> alcohol, hepatocellular carcinoma, FIB-4, multivariate logistic regression analyses, mortality.

Cancer Biotherapy and Radiopharmaceuticals
Capital Medical University (CN), Peking University (CN), Beijing Chao-Yang Hospital, Capital Medical University (CN), Chinese PLA General Hospital (CN), PLA Academy of Military Science (CN)
Openalex Percentile: Top 52%
Hepatocellular Carcinoma Treatment and Prognosis
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.